5,964Indexed clinical trials
LIVE
Explore Our Intelligence Platform
Connected clinical, company, disease, research and market intelligence.
Disease Intelligence
Explore current trial activity, sponsors, research signals and opportunity scores by disease area.
203 disease entities5,389 in-scope/related trials
Company Intelligence
Qualified sponsor profiles, recruiting activity, geographic exposure and therapeutic focus.
586 public profiles2,621 in-scope/related sponsors
Market Intelligence
Compare priority markets with research, clinical and machine-learning opportunity signals.
50 market profiles90% model confidence
AI Analyst BETA
Ask structured questions against the public intelligence layer and move into enterprise analysis when deeper work is needed.
Cited evidence-orientedFree quick analysis
Priority Markets
Current global opportunity scores from the live NeuroRisk model.
1United States92
2Australia87
3Canada86
4Germany85
5China84
6France82
Neuroscience Trial Activity
Current classified trial counts by disease area.
Parkinson's 978 · Alzheimer's 954 · Autism 762 · Epilepsy 740 · Depression 639 · ADHD 601
Featured Insight
AI Analyst Beta
Which organizations currently have the broadest indexed neuroscience trial activity?
Use the free analyst to inspect current sponsor, disease and market data. Enterprise workspaces add deeper comparisons, exports and recurring monitoring.
Built Around the Decision-Maker
Different workflows, one connected evidence layer.
Pharma & Biotech
Pipeline, portfolio, sponsor and market intelligence.
Explore → Clinical DevelopmentRecruiting, geography, phase and comparative trial signals.
Explore → BD & LicensingScreen organizations, indications and partnership opportunities.
Explore → InvestorsEvidence-linked diligence across companies and disease areas.
Explore → InsuranceDisease, market and research signals for strategic planning.
Explore → GovernmentCountry and public-health intelligence for policy research.
Explore →Evidence Before Marketing Claims
Enterprise buyers should be able to inspect what the system knows, when it was refreshed and how scores are produced.
Compare Before You Buy
Compare qualified sponsors side-by-side, then request an enterprise brief when you need exports, recurring surveillance or custom analysis.
Access That Scales With the Work
Start free; move to paid access when the workflow requires exports, API or enterprise support.
Free Intelligence
$0
- Public company, disease and market intelligence
- AI Analyst quick questions
- Sample reports
Developer API
$499/mo
- API-oriented workflows
- Structured intelligence access
- Evaluation support
Professional
$1,999/mo
- Advanced research workflow
- Comparisons and exports
- Priority intelligence use cases
Enterprise
$9,999/mo
- Organization-wide intelligence
- Enterprise API and tailored analysis
- Dedicated implementation path
Enterprise Access
Turn neuroscience intelligence into an operating advantage.
Bring your company, therapeutic area, market-entry or diligence question. NeuroRisk.ai will map the available evidence and the enterprise workflow required to answer it.